ORIC · ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals' Q1 2026 results reflect accelerated investment in its clinical pipeline, with R&D expenses rising 28% year-over-year to $31.4 million, driven by external costs for advancing rinzimetostat and enozertinib programs, partially offset by lower preclinical spending. G&A remained stable at $8.2 million. This contributed to a net loss of $35.8 million, or $(0.34) per share, on higher share count from ATM proceeds. Balance sheet strengthened significantly, with cash, equivalents, and investments reaching $419.7 million including $59.9 million raised via ATM, extending runway into 2H 2028 beyond the anticipated Phase 3 readout for rinzimetostat. CEO Jacob M. Chacko highlighted the pivotal selection of rinzimetostat 400 mg once daily as RP3D with darolutamide for the Himalayas-1 global Phase 3 trial in post-abiraterone mCRPC, set to initiate in 1H 2026. Dose optimization data showed a differentiated safety profile with mostly Grade 1 TRAEs, rare dose modifications, and strong efficacy including 84% 5-month rPFS, 47% PSA50 response, and 71% ctDNA reductions—outperforming standard therapies like Xtandi and Jevtana. Early post-AR inhibitor data reinforced durability. Enozertinib milestones include completed enrollment in EGFR exon 20 NSCLC monotherapy and ongoing trials, with multiple 2H 2026 updates. These advances position ORIC as a multi-asset late-stage oncology player.